Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer.
Selecting the correct and the most predictive animal models for your research is critical before entering the clinical efficacy studies. Choosing the right model can help determine the efficacy of your compound quickly and reliably.
When testing the preclinical efficacy of a new antitumor therapeutic, it is important to:
- Take into account the tumour microenvironment
- Test immunomodulatory drugs in intact immune systems
- Test compounds also in metastasized disease
- Evaluate the potential adverse effects on bone (cancer treatment-induced bone loss (CTIBL))
Find out more about Pharmatest's cancer and skeletal disease models by downloading this free whitepaper. Find out how to generate more accurate preclinical efficacy data, information about syngeneic models for testing anticancer efficacy of immunomodulators, why you should test your compound in a metastasis model, and how compounds can be bone-protective or rendering bone susceptible to metastasis.
Download to find out more.